middle.news
How Clarity’s Cu-SAR-bisPSMA is Shaping the Future of Prostate Cancer Treatment
9:56am on Thursday 15th of January, 2026 AEDT
•
Healthcare
Read Story
How Clarity’s Cu-SAR-bisPSMA is Shaping the Future of Prostate Cancer Treatment
9:56am on Thursday 15th of January, 2026 AEDT
Key Points
SECuRE Phase II trial continues with no protocol modifications
Nine participants showed mostly mild adverse events
66.7% achieved over 50% PSA reduction, 33.3% over 80%
One patient reached undetectable PSA and no detectable disease
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE